{"title":"用于检测伊朗中风患者血管性痴呆的 Addenbrooke's Cognitive Examination-III 的验证:二次数据分析。","authors":"Sajjad Rezaei, Karim Asgari Mobarake, Maryam Jafroudi, Alia Saberi, Mozaffar Hosseininezhad, Babak Bakhshayesh Eghbali, Ehsan Kazemnezhad Leyli","doi":"10.1080/23279095.2024.2429549","DOIUrl":null,"url":null,"abstract":"<p><p>The current study was conducted with the aim of evaluating the third version of Addenbrooke's Cognitive Examination (ACE-III), and exploring its diagnostic power for a sample of stroke patients in the Iranian population. This was a cross-sectional analytical study, in which 206 patients with stroke were compared with 200 normal individuals as the control group. The patients were diagnosed based on the findings of neuroimaging and clinical examination by a neurologist. ACE-III, Montreal Cognitive Assessment (MoCA), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), and The Structured Clinical Interview for DSM-5 (SCID-5) were used to gather the data and assess the vascular dementia in the patients. Furthermore, Cronbach's alpha, Pearson correlation coefficient, discriminant function analysis, and the receiver operating characteristic (ROC) curve were used to respectively measure internal consistency, convergent validity, discriminant validity, sensitivity, specificity, and the cutoff point of ACE-III. Internal consistency of ACE-III was excellent (α = 0.92 - 0.95), and convergent validity was measured through calculating the correlation between the scores of ACE-III and MoCA, which was very high (r = 0.957, P < 0.0001). Moreover, overall classification accuracy of ACE-III revealed that it is able to differentiate 87% of patients with vascular dementia from other patients. The area under the ROC curve was found to be 0.84, and cutoff point was 45/46, at which sensitivity and specificity were obtained as 0.72 and 0.90, respectively. ACE-III is a rapid, inexpensive, and efficient tool for evaluating cognitive deficits in specialized neurology clinics to provide a clinical and differential diagnosis of vascular dementia after stroke.</p>","PeriodicalId":51308,"journal":{"name":"Applied Neuropsychology-Adult","volume":" ","pages":"1-11"},"PeriodicalIF":1.4000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Validation of the Addenbrooke's Cognitive Examination-III for detecting vascular dementia in Iranian patients with stroke: A secondary data analysis.\",\"authors\":\"Sajjad Rezaei, Karim Asgari Mobarake, Maryam Jafroudi, Alia Saberi, Mozaffar Hosseininezhad, Babak Bakhshayesh Eghbali, Ehsan Kazemnezhad Leyli\",\"doi\":\"10.1080/23279095.2024.2429549\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The current study was conducted with the aim of evaluating the third version of Addenbrooke's Cognitive Examination (ACE-III), and exploring its diagnostic power for a sample of stroke patients in the Iranian population. This was a cross-sectional analytical study, in which 206 patients with stroke were compared with 200 normal individuals as the control group. The patients were diagnosed based on the findings of neuroimaging and clinical examination by a neurologist. ACE-III, Montreal Cognitive Assessment (MoCA), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), and The Structured Clinical Interview for DSM-5 (SCID-5) were used to gather the data and assess the vascular dementia in the patients. Furthermore, Cronbach's alpha, Pearson correlation coefficient, discriminant function analysis, and the receiver operating characteristic (ROC) curve were used to respectively measure internal consistency, convergent validity, discriminant validity, sensitivity, specificity, and the cutoff point of ACE-III. Internal consistency of ACE-III was excellent (α = 0.92 - 0.95), and convergent validity was measured through calculating the correlation between the scores of ACE-III and MoCA, which was very high (r = 0.957, P < 0.0001). Moreover, overall classification accuracy of ACE-III revealed that it is able to differentiate 87% of patients with vascular dementia from other patients. The area under the ROC curve was found to be 0.84, and cutoff point was 45/46, at which sensitivity and specificity were obtained as 0.72 and 0.90, respectively. ACE-III is a rapid, inexpensive, and efficient tool for evaluating cognitive deficits in specialized neurology clinics to provide a clinical and differential diagnosis of vascular dementia after stroke.</p>\",\"PeriodicalId\":51308,\"journal\":{\"name\":\"Applied Neuropsychology-Adult\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Applied Neuropsychology-Adult\",\"FirstCategoryId\":\"102\",\"ListUrlMain\":\"https://doi.org/10.1080/23279095.2024.2429549\",\"RegionNum\":4,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Neuropsychology-Adult","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1080/23279095.2024.2429549","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Validation of the Addenbrooke's Cognitive Examination-III for detecting vascular dementia in Iranian patients with stroke: A secondary data analysis.
The current study was conducted with the aim of evaluating the third version of Addenbrooke's Cognitive Examination (ACE-III), and exploring its diagnostic power for a sample of stroke patients in the Iranian population. This was a cross-sectional analytical study, in which 206 patients with stroke were compared with 200 normal individuals as the control group. The patients were diagnosed based on the findings of neuroimaging and clinical examination by a neurologist. ACE-III, Montreal Cognitive Assessment (MoCA), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), and The Structured Clinical Interview for DSM-5 (SCID-5) were used to gather the data and assess the vascular dementia in the patients. Furthermore, Cronbach's alpha, Pearson correlation coefficient, discriminant function analysis, and the receiver operating characteristic (ROC) curve were used to respectively measure internal consistency, convergent validity, discriminant validity, sensitivity, specificity, and the cutoff point of ACE-III. Internal consistency of ACE-III was excellent (α = 0.92 - 0.95), and convergent validity was measured through calculating the correlation between the scores of ACE-III and MoCA, which was very high (r = 0.957, P < 0.0001). Moreover, overall classification accuracy of ACE-III revealed that it is able to differentiate 87% of patients with vascular dementia from other patients. The area under the ROC curve was found to be 0.84, and cutoff point was 45/46, at which sensitivity and specificity were obtained as 0.72 and 0.90, respectively. ACE-III is a rapid, inexpensive, and efficient tool for evaluating cognitive deficits in specialized neurology clinics to provide a clinical and differential diagnosis of vascular dementia after stroke.
期刊介绍:
pplied Neuropsychology-Adult publishes clinical neuropsychological articles concerning assessment, brain functioning and neuroimaging, neuropsychological treatment, and rehabilitation in adults. Full-length articles and brief communications are included. Case studies of adult patients carefully assessing the nature, course, or treatment of clinical neuropsychological dysfunctions in the context of scientific literature, are suitable. Review manuscripts addressing critical issues are encouraged. Preference is given to papers of clinical relevance to others in the field. All submitted manuscripts are subject to initial appraisal by the Editor-in-Chief, and, if found suitable for further considerations are peer reviewed by independent, anonymous expert referees. All peer review is single-blind and submission is online via ScholarOne Manuscripts.